Enzon And Micromet To Host Technology Briefing On Single-Chain Antibody Collaboration.Business & Health Editors/Biotechnology Writers PISCATAWAY, N.J.--(BUSINESS WIRE)--April 25, 2002 -Technology Briefing to be Webcast Live- Enzon, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ENZN) and Micromet AG (private) will host a Technology Briefing discussing their strategic collaboration to develop novel single-chain antibody therapeutics. The briefing will be broadcast live over the internet on Thursday, May 9, 2002 at 9:00 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ) and will include presentations from Ulrich Grau, Chief Scientific Officer of Enzon and Patrick Baeuerle, Chief Scientific Officer of Micromet. Other members of management that will be in attendance include: Arthur Higgins, Chairman and Chief Executive Officer of Enzon, Kenneth Zuerblis, Vice President, Finance and Chief Financial Officer of Enzon and Christian Itin, Vice President of Business and Corporate Development of Micromet. All interested parties may access the call by using the following information: Domestic Dial-In Number: 888-280-8349 International Dial-In Number: 416-695-9701 Access Code 1898 The call will also be webcast in a "listen only" mode via the internet at http://www.vcall.com or http://www.enzon.com. Additionally, for those parties unable to listen at the time of the call, a telephone rebroadcast will be available following the call from Thursday, May 9, 2002 at approximately 1:00pm. This rebroadcast will end on Saturday, May 11, 2002 at 1:00pm. The rebroadcast may be accessed using the following information: Domestic Dial-In Number: 877-296-3929 International Dial-In Number: 416-695-6011 Access Code 1898 Enzon is a biopharmaceutical company that develops and commercializes enhanced therapeutics for life-threatening diseases through the application of its proprietary platform technologies: PEG Modification and single-chain antibodies (SCA (Single Connector Attachment) An 80-pin plug and socket used to connect peripherals. With a SCSI drive, it rolls three cables (power, data channel and ID configuration) into one connector for fast installation and removal. (R)). Three products are currently marketed which utilize Enzon's technology: PEG-INTRON marketed by Schering-Plough for hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. , ONCASPAR(R) for Acute Lymphoblastic Leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. (ALL), and ADAGEN(R) a treatment for a form of Severe Combined Immunodeficiency Disease Noun 1. severe combined immunodeficiency disease - a congenital disease affecting T cells that can result from a mutation in any one of several different genes; children with it are susceptible to infectious disease; if untreated it is lethal within the first year or (SCID SCID severe combined immunodeficiency (disease); see under immunodeficiency. SCID abbr. severe combined immunodeficiency SCID severe combined immunodeficiency disease. ), commonly known as the "Bubble Boy Disease." In addition to three approved products, Enzon has several products in various stages of clinical development by itself and with partners, including additional indications for PEG-INTRON with Schering-Plough. A Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the is being conducted for PEG-INTRON for the treatment of malignant melanoma Malignant Melanoma Definition Malignant melanoma is a type of cancer arising from the melanocyte cells of the skin. Melanocytes are cells in the skin that produce a pigment called melanin. . Enzon develops and markets products on its own, through strategic alliances and licensing arrangements, which in addition to Schering-Plough Corporation, include Alexion Pharmaceuticals, Inc., Baxter Healthcare Corporation, Bristol-Myers Squibb Company, Eli Lilly & Company, and Aventis. Micromet AG, a privately held, Munich-based biotechnology company, designs and develops innovative antibody-based drugs for the treatment of cancer, autoimmune and inflammatory diseases. The Company is building a broad pipeline of drug candidates on the basis of proprietary technologies with two candidates in Phase I clinical trials. Fundamental to Micromet's therapeutic strategy is the elimination of cells playing a pivotal role in the pathogenesis of human diseases by recruiting and activating immune effector cells. The Company has established the BiTE(TM) technology ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. , the most powerful `killer cells' of the human immune system. Micromet has integrated expertise and infrastructure in key drug development disciplines. The Company has investments from leading international life science investors with a cumulative financing volume of 68.2 million euros. (Minimum Requirements to listen to broadcast: The Windows Media Player Digital jukebox software for Windows from Microsoft that plays a variety of audio, video and streaming formats including MP3, WMA, CD audio and MIDI. Starting with Version 6.2 in 1999, the Windows Media Rights Manager was added for securing copyrighted content. software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp, and at least a 28.8Kbps connection to the Internet.). This release is also available at http://www.enzon.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion